Harrow HROW 深 沪
等待开盘 10-09 09:30:00 美东时间
30.52
-0.100
-0.33%
华盛通- 最 高31.11
- 今 开30.35
- 成交量 56.60万股
- 最 低 30.00
- 昨 收 30.62
- 总市值 114.41万
- 52周最高 54.85
- 市盈率 静 --
- 换手率 1509.84%
- 52周最低 28.5401
- 委 比 97.37%
- 总股本 3.75万
- 历史最高 59.23
- 量 比 0.98
- 振 幅 3.63%
- 历史最低 3.33
- 每 手 1
- 风险率 5.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
10-07 17:50
Harrow Closes TYRVAYA Acquisition, Expanding Dry Eye Portfolio
Harrow Health ( ($HROW) ) has shared an announcement. On October 1, 2026, Harro...
10-05 19:57
Harrow Closes Acquisition of TYRVAYA®
Harrow acquired TYRVAYA, the first FDA-approved nasal spray for dry eye disease (DED), expanding its ocular surface franchise. TYRVAYA, a cholinergic agonist, stimulates basal tear production via the trigeminal parasympathetic pathway and is approved in the U.S., China, and Taiwan. The acquisition includes worldwide rights except Japan, with Viatris retaining commercialization rights there. Harrow paid $30 million upfront, with up to $70 million ...
10-05 11:00
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Harrow will present 15 scientific abstracts at the American Academy of Optometry (AAOpt) Annual Meeting in Anaheim and the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans. These presentations cover dry eye disease, vernal keratoconjunctivitis (VKC), ocular inflammation, chronic blepharitis, and post-operative inflammation and pain. Featured products include VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®. The research includes Phas...
09-30 11:00
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
09-09 23:17
Harrow Health Streamlines Senior Finance and Accounting Leadership
An update from Harrow Health ( ($HROW) ) is now available. Effective September ...
09-05 05:21
William Blair updates its stock Conviction List
William Blair added BJ’s Restaurants (BJRI), Aehr Test Systems (AEHR), MP Materials (MP), APi Group (APG), BrightSpring Health Services (BTSG), Curtiss-Wright (CW), James Hardie Industries (JHX) and U...
09-01 19:59
Harrow to Participate in Three Investor Conferences in September
Harrow, a leading provider of ophthalmic disease management solutions, announced its participation in three investor conferences in September 2026 in New York. The company will attend the 2026 Cantor Global Healthcare Conference on September 9, the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. The fireside chats at Cantor and ...
09-01 11:00
